<DOC>
	<DOCNO>NCT00934154</DOCNO>
	<brief_summary>This multi-centre Phase III randomize control study patient multiple myeloma ( MM ) . Eligible patient candidate transplantation randomize receive eight course Melphalan/Prednisolone without Thalidomide treatment . Thalidomide initiate dose 100 mg/day maintain 100 mg/day . The patient assess response end 2nd , 4th , 6th 8th cycle treatment . The toxicity assess monthly interval . Patients assess : 1 . Incidence grade toxicity 2 . Level maximum disease response 3 . Time disease progression 4 . Time death</brief_summary>
	<brief_title>Melphalan+Prednisolon With Without Thalidomide Previously Untreated Elderly Patients With Multiple Myeloma</brief_title>
	<detailed_description>This trial include patient candidate transplantation age 55 . Treatment cycle include ( MP ) melphalan ( 9 mg /sq.m/day d1-4 ) , prednisolone ( 60 mg/sq.m/d , d1-4 ) every six week maximum 8 cycle . Patients randomise ( MPT ) Thalidomide ( 1:1 ) 100 mg/day continuously . Cross-over MPT allow insufficient response obtain MP arm . response evaluate every cycle . At end 12 month treatment patient follow progress death . Second line treatment define .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Age 55 year old . Diagnosis MM ( Appendix A ) staging ( Appendix B ) , previously untreated . Performance status ECOG , 0 , 1 , 2 ( Appendix C ) . Written inform consent study medication bone marrow biopsy diagnosis , 12 week 6 month and/or offstudy assessment . Women pregnant lactating time diagnosis ineligible . All woman childbearing potential must negative pregnancy test within 24hrs commence thalidomide must take adequate precaution prevent pregnancy plan conceive child treatment program : Adequate precaution define `` least one highly effective method i.e. , IUD , hormonal ( birth control pill , injection , implant ) , tubal ligation , partner 's vasectomy AND one additional effective method i.e. , latex condom , diaphragm , cervical cap '' . Women become pregnant protocol remove immediately protocol . Male patient ( include patient vasectomy ) must use barrier contraception four week complete thalidomide . Patients remain eligible presence abnormal renal function and/or liver function time enrollment . Absence severe dementia , able take medication home . Absence systemic disorder ( gastrointestinal , pulmonary , cardiac neurological ) . Asymptomatic myeloma solitary plasmacytoma bone extramedullary plasmacytoma ( without evidence myeloma ) . Previous concurrent active malignancy , except surgically remove basal cell carcinoma skin situ carcinoma . Previous treatment myeloma , except minimal local radiotherapy relieve bone pain . Other illness would preclude chemotherapy administration patient compliance . Any serious medical psychiatric illness would prevent informed consent . Peripheral neuropathy &gt; NCI criterion grade 2 . Pregnant lactating woman patient childbearing age refuse use contraception . History hypersensitivity thalidomide component medication .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>multiple myeloma</keyword>
	<keyword>thalidomide</keyword>
	<keyword>melphalan</keyword>
	<keyword>prednisolone</keyword>
	<keyword>newly diagnose</keyword>
	<keyword>elderly</keyword>
	<keyword>eligible transplantation</keyword>
</DOC>